PMID- 24409449
OWN - NLM
STAT- MEDLINE
DCOM- 20150122
LR  - 20211021
IS  - 2326-6074 (Electronic)
IS  - 2326-6066 (Print)
IS  - 2326-6066 (Linking)
VI  - 1
IP  - 2
DP  - 2013 Aug
TI  - Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer 
      genome atlas.
PG  - 112-22
LID - 10.1158/2326-6066.CIR-13-0028 [doi]
AB  - PURPOSE: The molecular heterogeneity of glioblastoma has been well recognized and 
      has resulted in the generation of molecularly defined subtypes. These subtypes 
      (classical, neural, mesenchymal, and proneural) are associated with particular 
      signaling pathways and differential patient survival. Less understood is the 
      correlation between these glioblastoma subtypes with immune system effector 
      responses, immune suppression and tumor-associated and tumor-specific antigens. 
      The role of the immune system is becoming increasingly relevant to treatment as 
      new agents are being developed to target mediators of tumor-induced immune 
      suppression which is well documented in glioblastoma. EXPERIMENTAL DESIGN: To 
      ascertain the association of antigen expression, immune suppression, and effector 
      response genes within glioblastoma subtypes, we analyzed the Cancer Genome Atlas 
      (TCGA) glioblastoma database. RESULTS: We found an enrichment of genes within the 
      mesenchymal subtype that are reflective of anti-tumor proinflammatory responses, 
      including both adaptive and innate immunity and immune suppression. CONCLUSIONS: 
      These results indicate that distinct glioma antigens and immune genes demonstrate 
      differential expression between glioblastoma subtypes and this may influence 
      responses to immune therapeutic strategies in patients depending on the subtype 
      of glioblastoma they harbor.
FAU - Doucette, Tiffany
AU  - Doucette T
AD  - Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 
      Houston, Texas, 77030.
FAU - Rao, Ganesh
AU  - Rao G
AD  - Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 
      Houston, Texas, 77030.
FAU - Rao, Arvind
AU  - Rao A
AD  - Department of Bioinformatics and Computational Biology, The University of Texas 
      M. D. Anderson Cancer Center, Houston, Texas, 77030.
FAU - Shen, Li
AU  - Shen L
AD  - Department of Bioinformatics and Computational Biology, The University of Texas 
      M. D. Anderson Cancer Center, Houston, Texas, 77030.
FAU - Aldape, Kenneth
AU  - Aldape K
AD  - Department of Neuropathology, The University of Texas M. D. Anderson Cancer 
      Center, Houston, Texas, 77030.
FAU - Wei, Jun
AU  - Wei J
AD  - Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 
      Houston, Texas, 77030.
FAU - Dziurzynski, Kristine
AU  - Dziurzynski K
AD  - Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 
      Houston, Texas, 77030.
FAU - Gilbert, Mark
AU  - Gilbert M
AD  - Department of Neuro-Oncology, The University of Texas M. D. Anderson Cancer 
      Center, Houston, Texas, 77030.
FAU - Heimberger, Amy B
AU  - Heimberger AB
AD  - Department of Neurosurgery, The University of Texas M. D. Anderson Cancer Center, 
      Houston, Texas, 77030.
LA  - eng
GR  - R01 CA120813/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - K08 NS070928/NS/NINDS NIH HHS/United States
GR  - NIH RO1-CA1208113/CA/NCI NIH HHS/United States
GR  - P50 CA127001/CA/NCI NIH HHS/United States
GR  - 5P50 CA127001/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Immunol Res
JT  - Cancer immunology research
JID - 101614637
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cytokines)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Antigens, Neoplasm/genetics/immunology
MH  - Brain Neoplasms/classification/*genetics/*immunology/pathology
MH  - Cytokines/genetics/immunology
MH  - Gene Expression Regulation, Neoplastic/immunology
MH  - Genome, Human
MH  - Glioblastoma/classification/*genetics/*immunology/pathology
MH  - Humans
MH  - Immune Tolerance/genetics
MH  - Mesoderm/immunology/pathology
MH  - RNA, Messenger/biosynthesis/genetics
PMC - PMC3881271
MID - NIHMS525712
OTO - NOTNLM
OT  - glioblastoma
OT  - immune activation
OT  - immune suppression
OT  - tumor antigens
COIS- Disclosure of Potential Conflicts of Interest No potential conflicts of interest 
      are disclosed.
EDAT- 2014/01/11 06:00
MHDA- 2015/01/23 06:00
PMCR- 2014/08/01
CRDT- 2014/01/11 06:00
PHST- 2014/01/11 06:00 [entrez]
PHST- 2014/01/11 06:00 [pubmed]
PHST- 2015/01/23 06:00 [medline]
PHST- 2014/08/01 00:00 [pmc-release]
AID - 10.1158/2326-6066.CIR-13-0028 [doi]
PST - ppublish
SO  - Cancer Immunol Res. 2013 Aug;1(2):112-22. doi: 10.1158/2326-6066.CIR-13-0028.